Related Experiment Video

Updated: Jul 31, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

312

Association of Heart Failure Patients With and Without Sacubitril-Valsartan Use With Incident Cancer Risk

Wei-Syun Hu1,2, Cheng-Li Lin3

  • 1School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.

Journal of Cardiovascular Pharmacology
|May 3, 2023
PubMed

Insights

This study investigated cancer risk in heart failure patients using sacubitril-valsartan versus those not using it. Sacubitril-valsartan use was associated with a significantly lower risk of developing cancer.

Area of Science:

  • Cardiology
  • Oncology

Background:

  • Heart failure (HF) is a complex cardiovascular condition.
  • Understanding the long-term implications of HF treatments on other health outcomes is crucial.

Purpose of the Study:

  • To evaluate the association between sacubitril-valsartan use and incident cancer risk in patients with heart failure.
  • To compare cancer incidence rates between patients treated with sacubitril-valsartan and a control group.

Main Methods:

  • A cohort study involving 18,072 patients receiving sacubitril-valsartan and 18,072 controls.
  • The Fine and Gray model was employed to estimate subhazard ratios (SHRs) for cancer development.
  • Adjusted SHRs and 95% confidence intervals (CIs) were calculated.

Main Results:

  • Cancer incidence rates were 12.02 per 1000 person-years (sacubitril-valsartan) vs. 23.31 per 1000 person-years (control).
  • Sacubitril-valsartan users exhibited a significantly lower risk of developing cancer.
  • The adjusted SHR for cancer was 0.60 (95% CI: 0.51, 0.71) for sacubitril-valsartan users.

Conclusions:

  • Sacubitril-valsartan use in heart failure patients is associated with a reduced risk of incident cancer.
  • Further research may explore the mechanisms behind this observed association.

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.5K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

153

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
474
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
17
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
405
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
173
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
433
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
19